	US 12,264,178 B2
	Ursolic acid morpholine and diethanolamine salts
John J. Talley, St. Louis, MO (US)
Assigned to EMMYON, INC., Rochester, MN (US)
Filed by EMMYON, INC., Rochester, MN (US)
Filed on Oct. 9, 2024, as Appl. No. 18/910,781.
Application 18/910,781 is a division of application No. 16/811,730, filed on Mar. 6, 2020.
Application 16/811,730 is a continuation in part of application No. PCT/US2018/049742, filed on Sep. 6, 2018.
Claims priority of provisional application 62/649,938, filed on Mar. 29, 2018.
Claims priority of provisional application 62/558,004, filed on Sep. 13, 2017.
Prior Publication US 2025/0034203 A1, Jan. 30, 2025
Int. Cl. A61K 45/06 (2006.01); A23L 29/00 (2016.01); C07J 63/00 (2006.01)

CPC C07J 63/008 (2013.01) [A23L 29/03 (2016.08); A61K 45/06 (2013.01)]

34 Claims

1. A method for:

(i) increasing skeletal muscle mass;

(ii) treating skeletal muscle atrophy;

(iii) reducing muscle atrophy;

(iv) treating sarcopenia;

(v) treating cachexia;

(vi) increasing strength;

(vii) treating weakness;

(viii) reducing weakness;

(ix) increasing exercise capacity;

(x) promoting muscle growth;

(xi) increasing the ratio of skeletal muscle to fat;

(xii) reducing fat;

(xiii) treating obesity;

(xiv) treating diabetes;

(xv) lowering blood glucose;

(xvi) treating pre-diabetes;

(xvii) treating metabolic syndrome; or

(xviii) treating insulin resistance;

in a subject in need thereof, the method comprising administering to the subject an effective amount of an ursolic acid salt selected from ursolic acid diethanolamine salt and ursolic acid morpholine salt.